7 results
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
inhibitors • Injection drug ... Tuberculin skin test ... Treatment: Active ... Initiating Treatment ... #Management #Treatment
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
inhibitors • Injection drug ... Tuberculin skin test ... Treatment: Active ... Initiating Treatment ... #Management #Treatment
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
Mycobacterium Tuberculosis ... disease) Indications ... #Treatment #management ... #opportunistic ... infections #HIVAIDS #pharmacology
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
Individualized Treatment ... Resistant Tuberculosis ... #MDRTB #management ... #Treatment #antimicrobials ... #regimens #pharmacology
Treatment Options for Helicobacter Pylori and Peptic Ulcer Disease

Active Helicobacter pylori—associated ulcer
1. Treat with anti—H pylori
with urea breath test ... fecal antigen test ... the preferred drugs ... #Management #Pharmacology ... #Medications
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
Prophylaxis): Indications ... Note: Active TB ... IDSA #Prevention #Treatment ... #management #opportunistic ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Cytomegalovirus Infections in HIV-AIDS
Preventing CMV Disease:
 • CMV end-organ disease is best
end-organ disease is best ... ., concomitant medications ... intraocular levels of drug ... #management #opportunistic ... infections #HIVAIDS #pharmacology